Merck/MedImmune
Executive Summary
Collaboration on MEDI-488 anti-HIV monoclonal antibody will continue following a review that began in January of the available data ("The Pink Sheet" Jan. 11, T&G-8), Gaithersburg, Md.-based MedImmune reports March 4. The companies have modified their autumn 1991 three-year deal: Merck will fund internal development of MEDI-488 but defer MedImmune research on other anti-HIV MAbs at least until after Phase I trials of MEDI-488.
|
Collaboration on MEDI-488 anti-HIV monoclonal antibody will
continue following a review that began in January of the available
data ("The Pink Sheet" Jan. 11, T&G-8), Gaithersburg, Md.-based
MedImmune reports March 4. The companies have modified their autumn
1991 three-year deal: Merck will fund internal development of
MEDI-488 but defer MedImmune research on other anti-HIV MAbs at
least until after Phase I trials of MEDI-488. |